After COVID-19, BioNTech Plans To Develop an mRNA Vaccine To Prevent Malaria

by Vandana Singh, Benzinga Editor

July 26, 2021 10:24 AM | 26 seconds read |

BioNTech SE BNTX has announced that it plans to develop an mRNA-based vaccine to prevent Malaria, a mosquito-borne illness.
The Company aims to begin clinical trials for the shot by the end of 2022.
BioNTech said it would assess multiple vaccine candidates that target the circumsporozoite protein (CSP), as well as new antigens discovered in pre-clinical research.
Price Action: BNTX shares are up 3.72% at $292.44 during the market session on the last check Monday.

Posted In: Biotech Long Ideas News Health Care Movers Trading Ideas General Briefs malaria

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.